Recent in vivo data has suggested that the inhibition of KRAS G12C using AMG510 creates a pro-inflammatory tumor microenvironment, promoting the anti-tumor activity of immune cells alone and in combination with immune CPIs (227). The gene discussed is KRAS; the disease is neoplasm.